Download
liver pathophysiology and manifestations of portal hypertension n.
Skip this Video
Loading SlideShow in 5 Seconds..
Liver Pathophysiology and Manifestations of Portal Hypertension PowerPoint Presentation
Download Presentation
Liver Pathophysiology and Manifestations of Portal Hypertension

Liver Pathophysiology and Manifestations of Portal Hypertension

270 Views Download Presentation
Download Presentation

Liver Pathophysiology and Manifestations of Portal Hypertension

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Liver Pathophysiology and Manifestations of Portal Hypertension Evan Pivalizza November 2008

  2. Physiology blood supply • 25% CO • HA: 25% HBF, 45-50% O2 • PV: 75% HBF, 50-55% O2 • Flow ∞ pre-portal arterioles • Flow + Resistance thru liver = portal pressure • PV: Presinusoidal(pre-capillary) + post-sinusoidal → venous resistance via SNS stimulation

  3. Portal hypertension • ↑ blood flow into system • Resistance portal system or portacaval collaterals • → ↓ PV flow (partial compensation ↑ HA flow) • O2 supply may be maintained • Total HBF ↓

  4. Pharmacokinetics Hepatic extraction  • HBF • Protein binding ( albumin – acidic drugs, alpha1 acid Gp often ↑ - basic drugs) • Intrinsic ability hepatic enzymes clear drug

  5. Highly extracted –  HBF • Morphine, lidocaine, midazolam (Cl fent/sufent , alfent ) • Poorly extracted drugs – Cl independent HBF • Highly protein bound • Diazepam, lorazepam, coumadin, phenytoin • Less protein binding • STP

  6. Hypoxemia in Liver Disease • Causes • Infection • Pleural effusion/ascites/hydrothorax (V/Q mismatch) • Hepato-Pulmonary Syndrome • Intrapulmonary VD • Vascular alterations lung tissue • Preop hypoxemia (indication for transplant) • ↑ mortality if PaO2 < 50 • Orthodeoxia (worse with standing)

  7. Diagnosis HPS • 4 - 25% incidence • ↑ A-a gradient (RA PaO2 < 70) • Intrapulmonary vascular dilations • Contrast TTE/TEE • Delayed contrast-enhanced echo (3-6 cycles vs. direct shunt – 1-2) - bubbles normally trapped alveoli → LA > 3 cardiac cycles • Technetium labeled albumin

  8. Treatment • Pressure controlled or limited TV • PEEP (maintain CO to sustain HBF) – NOT over PEEP • Consider prone

  9. Porto-Pulmonary Hypertension • Def: MPAP > 25 (rest), 30 (exercise), PCWP < 15, PVR > 240 (125) • Mild (<35), moderate (<45), severe (> 45 -periop mortality > 50%) • Volume overload • High CO • Cardiomyopathy

  10. MPAP < 35, PVR < 240, good cardiac function = proceed • MPAP > 35, attempt VD Rx • MPAP > 40, PVR > 240 = delay

  11. Rx: Plt aggregation/VC/endothelial proliferation • Oral • Endothelin antagonists (Bosentan) • Sildenafil • Simvastatin • Inhaled – NO, prostacycline • IV – Epoprosetenol + usual aids RV function (PDE inhibitors etc)

  12. HepatoRenal Syndrome • Predisposed renal failure • Radiocontrast imaging • NSAIDs • Hypovolemia variceal hemorrhage • HRS

  13. 17% pts admitted with ascites • 50% pts - die liver failure • Reversible renal VC + mild systemic hypotension • Kidney structurally normal (imbalance VC/VD mediators)

  14. Type 1 • Acute, progressive, 80% mortality • Type 2 • Diuretic resistant ascites, slow progression

  15. Rx: • Volume (albumin, esp. with paracentesis) • Systemic VC (terlipressin, vasopressin) • Transplant (liver + kidney)

  16. Coagulation • ↓ fibrinogen, II, V, VII, IX, X • Also, ↓coag inhibitors (ATIII, protein C,S) • Thrombocytopenia (hypersplenism) • Platelet function defect • ↑ fibrinolysis • ↑ FDPs → ↓ plt function (Ib binding) • ↓ Plasminogen activator inhibitor • Primary (vs. secondary – to activated thrombosis)